Patricia A Cronin1, Anya Romanoff1, Emily C Zabor2, Michelle Stempel1, Anne Eaton2, Lillian M Smyth3, Alice Y Ho4, Monica Morrow1, Mahmoud El-Tamer1, Mary L Gemignani5. 1. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. gemignam@mskcc.org.
Abstract
BACKGROUND: Low incidence of breast cancer in men (BCM) (< 1% of all breast cancers) has led to a paucity of outcome data. This study evaluated the impact of age on BCM outcomes. METHODS: For this study, BCM patients treated between 2000 and 2011 were stratified by age (≤ 65 or > 65 years). Kaplan-Meier methods were used to compare overall survival (OS) and breast cancer-specific survival (BCSS). Competing-risk methods analyzed time to second primary cancers (SPCs), with any-cause death treated as a competing risk. RESULTS: The study identified 152 BCM patients with a median age of 64 years (range 19-96 years). The median body mass index (BMI) was 28 kg/m2. Men age 65 years or younger (n = 78, 51%) were more overweight/obese than men older than 65 years (n = 74, 49%) (89% vs 74%, respectively; P = 0.008). Both groups had similar nodal metastases rates (P = 0.4), estrogen receptor positivity (P = 1), and human epidermal growth factor receptor 2 (HER2)neu overexpression (P = 0.6). Men 65 years of age or younger were more likely to receive chemotherapy (P = 0.002). The median follow-up period was 5.8 years (range 0.1-14.4 years). The 5-year OS was 86% (95% confidence interval [CI] 80-93%), whereas the 5-year BCSS was 95% (95% CI 91-99%). The BCM patients 65 years of age and younger had better OS (P = 0.003) but not BCSS (P = 0.8). The 5-year cumulative incidence of SPC was 8.4% (95% CI 3.4-13.4%). The prior SPC rate was higher for men older than 65 years (n = 20, 31%) than for those age 65 years or younger (n = 7, 11%) (P = 0.008). This did not account for differences in life years at risk. No difference was observed in SPC cumulative incidence stratified by age (P = 0.3). CONCLUSIONS: Men 65 years of age or younger received more chemotherapy and had improved OS, but not BCSS, compared with men older than 65 years. For all BCM, SPC is a risk, and appropriate screening may be warranted.
BACKGROUND: Low incidence of breast cancer in men (BCM) (< 1% of all breast cancers) has led to a paucity of outcome data. This study evaluated the impact of age on BCM outcomes. METHODS: For this study, BCMpatients treated between 2000 and 2011 were stratified by age (≤ 65 or > 65 years). Kaplan-Meier methods were used to compare overall survival (OS) and breast cancer-specific survival (BCSS). Competing-risk methods analyzed time to second primary cancers (SPCs), with any-cause death treated as a competing risk. RESULTS: The study identified 152 BCMpatients with a median age of 64 years (range 19-96 years). The median body mass index (BMI) was 28 kg/m2. Men age 65 years or younger (n = 78, 51%) were more overweight/obese than men older than 65 years (n = 74, 49%) (89% vs 74%, respectively; P = 0.008). Both groups had similar nodal metastases rates (P = 0.4), estrogen receptor positivity (P = 1), and humanepidermal growth factor receptor 2 (HER2)neu overexpression (P = 0.6). Men 65 years of age or younger were more likely to receive chemotherapy (P = 0.002). The median follow-up period was 5.8 years (range 0.1-14.4 years). The 5-year OS was 86% (95% confidence interval [CI] 80-93%), whereas the 5-year BCSS was 95% (95% CI 91-99%). The BCMpatients 65 years of age and younger had better OS (P = 0.003) but not BCSS (P = 0.8). The 5-year cumulative incidence of SPC was 8.4% (95% CI 3.4-13.4%). The prior SPC rate was higher for men older than 65 years (n = 20, 31%) than for those age 65 years or younger (n = 7, 11%) (P = 0.008). This did not account for differences in life years at risk. No difference was observed in SPC cumulative incidence stratified by age (P = 0.3). CONCLUSIONS:Men 65 years of age or younger received more chemotherapy and had improved OS, but not BCSS, compared with men older than 65 years. For all BCM, SPC is a risk, and appropriate screening may be warranted.
Authors: Sabine Rohrmann; Meredith S Shiels; David S Lopez; Nader Rifai; William G Nelson; Norma Kanarek; Eliseo Guallar; Andy Menke; Corinne E Joshu; Manning Feinleib; Siobhan Sutcliffe; Elizabeth A Platz Journal: Cancer Causes Control Date: 2011-06-16 Impact factor: 2.506
Authors: Mahmoud B El-Tamer; Ian K Komenaka; Andrea Troxel; Huiling Li; Kathie-Ann Joseph; Beth-Ann Ditkoff; Freya R Schnabel; David W Kinne Journal: Arch Surg Date: 2004-10
Authors: Stacey B Leibowitz; Judy E Garber; Edward A Fox; Massimo Loda; Donald S Kaufman; Philip W Kantoff; William K Oh Journal: Breast J Date: 2003 May-Jun Impact factor: 2.431
Authors: B Cutuli; M Lacroze; J M Dilhuydy; M Velten; B De Lafontan; C Marchal; M Resbeut; Y Graic; F Campana; V Moncho-Bernier Journal: Eur J Cancer Date: 1995-11 Impact factor: 9.162
Authors: Louise A Brinton; Michael B Cook; Valerie McCormack; Kenneth C Johnson; Håkan Olsson; John T Casagrande; Rosie Cooke; Roni T Falk; Susan M Gapstur; Mia M Gaudet; J Michael Gaziano; Georgios Gkiokas; Pascal Guénel; Brian E Henderson; Albert Hollenbeck; Ann W Hsing; Laurence N Kolonel; Claudine Isaacs; Jay H Lubin; Karin B Michels; Eva Negri; Dominick Parisi; Eleni Th Petridou; Malcolm C Pike; Elio Riboli; Howard D Sesso; Kirk Snyder; Anthony J Swerdlow; Dimitrios Trichopoulos; Giske Ursin; Piet A van den Brandt; Stephen K Van Den Eeden; Elisabete Weiderpass; Walter C Willett; Marianne Ewertz; David B Thomas Journal: J Natl Cancer Inst Date: 2014-02-19 Impact factor: 13.506
Authors: Bridget N Kelly; Heather R Faulkner; Barbara L Smith; Jenna E Korotkin; Conor R Lanahan; Carson Brown; Michele A Gadd; Michelle C Specht; Kevin S Hughes; T Salewa Oseni; Amy S Colwell; Suzanne B Coopey Journal: Ann Surg Oncol Date: 2021-09-08 Impact factor: 5.344
Authors: Kamal Eldin Ahmed Abdelsalam; Mohammed Asad; Monjid Ahmed Ibrahim Ahmed; Syed Mohammed Basheeruddin Asdaq; Yahya Mohzari; Ahmed Alrashed; NajwaJilan Alghamdi; Kholoud Nasser Alrami; Wael Ahmed Alharbi Journal: Int J Environ Res Public Health Date: 2021-05-01 Impact factor: 3.390